Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

NCT00002161 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00002161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3
Lead sponsor
Gilead Sciences
Phase
Not applicable
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
400
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections